BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $62,145 | +62.6% | 2,357 | +6.0% | 0.00% | – |
| Q2 2023 | $38,230 | +12.8% | 2,223 | +8.7% | 0.00% | – |
| Q1 2023 | $33,903 | +160.8% | 2,045 | +13.0% | 0.00% | – |
| Q4 2022 | $13,000 | -27.8% | 1,810 | -2.4% | 0.00% | – |
| Q3 2022 | $18,000 | 0.0% | 1,855 | -4.4% | 0.00% | – |
| Q2 2022 | $18,000 | 0.0% | 1,941 | +7.3% | 0.00% | – |
| Q1 2022 | $18,000 | -35.7% | 1,809 | +4.8% | 0.00% | – |
| Q4 2021 | $28,000 | -70.2% | 1,726 | -14.0% | 0.00% | – |
| Q3 2021 | $94,000 | -23.0% | 2,007 | 0.0% | 0.00% | – |
| Q2 2021 | $122,000 | +19.6% | 2,007 | +20.5% | 0.00% | – |
| Q1 2021 | $102,000 | -19.7% | 1,666 | -6.8% | 0.00% | – |
| Q4 2020 | $127,000 | +159.2% | 1,788 | +37.0% | 0.00% | – |
| Q3 2020 | $49,000 | +14.0% | 1,305 | 0.0% | 0.00% | – |
| Q2 2020 | $43,000 | +79.2% | 1,305 | +57.2% | 0.00% | – |
| Q1 2020 | $24,000 | – | 830 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |